Cutaneous melanoma with myxoid features: twelve cases with differential diagnosis
- PMID: 10584704
- DOI: 10.1097/00000478-199912000-00008
Cutaneous melanoma with myxoid features: twelve cases with differential diagnosis
Abstract
Substantial myxoid change can occur in malignant melanoma, but its importance in primary disease has not been systematically evaluated. This report describes the clinical, microscopic, histochemical, and immunohistochemical findings in 12 patients with primary cutaneous malignant melanoma with myxoid features. The tumors presented as solitary lesions situated on the limbs (six lesions), trunk (four lesions), and head and neck (two lesions). The patients included six women and six men, whose ages ranged from 26 to 95 years, with a mean of 63 years. Breslow thickness varied from 0.48 mm to more than 12 mm, with a mean of more than 3.2 mm. Clinical follow-up for an average of 22 months showed one local recurrence, but no evidence of metastases yet. In all cases, there was a combination of myxoid and nonmyxoid areas. A minimum of 15% myxoid cross-sectional area was required for inclusion in the study, and up to 80% was observed. The pale blue mucin identified on hematoxylin and eosin staining was sensitive to hyaluronidase and positive for alcian blue in the 10 cases stained. Immunohistochemical staining was positive for S-100 in all 9 cases stained, positive for HMB-45 in 9 (90%) of 10, and negative for cytokeratin in all 9 cases in which myxoid melanoma remained in the block after previous sections. The presence of myxoid stroma did not define a biologically significant subgroup of melanoma. Only in cases with extensive (>50%) myxoid stromal effacement of the melanoma was there a major diagnostic hurdle. The diagnosis of primary cutaneous melanoma with myxoid features was seldom as problematic as metastatic myxoid melanoma. Positive S-100 stains, negative cytokeratin immunohistochemical stains, and hyaluronidase-sensitive alcian blue staining assisted in the diagnosis of this entity.
Similar articles
-
HMB-45, S-100, NK1/C3, and MART-1 in metastatic melanoma.Hum Pathol. 2004 Feb;35(2):217-23. doi: 10.1016/j.humpath.2003.09.019. Hum Pathol. 2004. PMID: 14991540
-
Epithelial markers in malignant melanoma. A study of primary lesions and their metastases.Am J Dermatopathol. 1994 Jun;16(3):241-6. doi: 10.1097/00000372-199406000-00003. Am J Dermatopathol. 1994. PMID: 7524376
-
Myxoid malignant melanoma. A previously undescribed histologic pattern noted in metastatic lesions and a report of four cases.Am J Surg Pathol. 1986 Mar;10(3):203-11. Am J Surg Pathol. 1986. PMID: 3953941
-
Histologic spectrum of neurothekeoma and the value of immunoperoxidase staining for S-100 protein in distinguishing it from melanoma.Am J Dermatopathol. 1994 Oct;16(5):496-503. doi: 10.1097/00000372-199410000-00004. Am J Dermatopathol. 1994. PMID: 7528475 Review.
-
Unusual variants of malignant melanoma.Mod Pathol. 2006 Feb;19 Suppl 2:S41-70. doi: 10.1038/modpathol.3800516. Mod Pathol. 2006. PMID: 16446716 Review.
Cited by
-
Cytomorphological Spectrum of Malignant Melanoma: A 3-Year Study in a Tertiary Care Centre in India.Indian J Dermatol. 2023 May-Jun;68(3):257-260. doi: 10.4103/ijd.ijd_548_22. Indian J Dermatol. 2023. PMID: 37529442 Free PMC article.
-
Unusual histologic and clinical variants of melanoma: implications for therapy.Curr Oncol Rep. 2007 Sep;9(5):403-10. doi: 10.1007/s11912-007-0055-7. Curr Oncol Rep. 2007. PMID: 17706169 Review.
-
Unusual histologic and clinical variants of melanoma: implications for therapy.Curr Treat Options Oncol. 2006 May;7(3):169-80. doi: 10.1007/s11864-006-0010-0. Curr Treat Options Oncol. 2006. PMID: 16615873 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical